{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T04:26:26Z","timestamp":1774326386447,"version":"3.50.1"},"reference-count":62,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2013,12,1]],"date-time":"2013-12-01T00:00:00Z","timestamp":1385856000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,12,1]],"date-time":"2013-12-01T00:00:00Z","timestamp":1385856000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1136\/annrheumdis-2012-202220","type":"journal-article","created":{"date-parts":[[2012,12,8]],"date-time":"2012-12-08T02:19:52Z","timestamp":1354933192000},"page":"1947-1955","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":328,"title":["The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: a systematic review of the literature with a meta-analysis"],"prefix":"10.1016","volume":"72","author":[{"given":"Sandra","family":"Garc\u00eas","sequence":"first","affiliation":[]},{"given":"Jocelyne","family":"Demengeot","sequence":"additional","affiliation":[]},{"given":"Elizabeth","family":"Benito-Garcia","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"key":"10.1136\/annrheumdis-2012-202220_bib1","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.autrev.2011.01.001","article-title":"Switching rheumatoid arthritis treatments: an update","volume":"10","author":"Atzeni","year":"2011","journal-title":"Autoimmun Rev"},{"key":"10.1136\/annrheumdis-2012-202220_bib2","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1001\/jama.2011.406","article-title":"Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up","volume":"305","author":"Bartelds","year":"2011","journal-title":"JAMA"},{"key":"10.1136\/annrheumdis-2012-202220_bib3","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1136\/ard.2007.072397","article-title":"Decreased clinical response to infliximab in ankylosing spondylitis is correlated with anti-infliximab formation","volume":"66","author":"de Vries","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2012-202220_bib4","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1056\/NEJMoa020888","article-title":"Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease","volume":"348","author":"Baert","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1136\/annrheumdis-2012-202220_bib5","doi-asserted-by":"crossref","first-page":"256","DOI":"10.4161\/mabs.2.3.11641","article-title":"The immunogenicity of humanized and fully human antibodies: residual immunogenicity resides in the CDR regions","volume":"2","author":"Harding","year":"2010","journal-title":"MAbs"},{"key":"10.1136\/annrheumdis-2012-202220_bib6","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.coi.2008.06.011","article-title":"Immunogenicity of anti-tumor necrosis factor antibodies-toward improved methods of anti-antibody measurement","volume":"20","author":"Aarden","year":"2008","journal-title":"Curr Opin Immunol"},{"key":"10.1136\/annrheumdis-2012-202220_bib7","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.jim.2010.03.012","article-title":"Rheumatoid factor interference in immunogenicity assays for human monoclonal antibody therapeutics","volume":"357","author":"Tatarewicz","year":"2010","journal-title":"J Immunol Methods"},{"key":"10.1136\/annrheumdis-2012-202220_bib8","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1172\/JCI112027","article-title":"Anti-Fab antibodies in humans. Predominance of minor immunoglobulin G subclasses in rheumatoid arthritis","volume":"76","author":"Persselin","year":"1985","journal-title":"J Clin Invest"},{"key":"10.1136\/annrheumdis-2012-202220_bib9","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S0022-1759(99)00206-9","article-title":"The influence of naturally occurring heterophilic anti-immunoglobulin antibodies on direct measurement of serum proteins using sandwich ELISAs","volume":"235","author":"Hennig","year":"2000","journal-title":"J Immunol Methods"},{"key":"10.1136\/annrheumdis-2012-202220_bib10","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.jim.2011.07.019","article-title":"Differential effect of drug interference in immunogenicity assays","volume":"372","author":"Hart","year":"2011","journal-title":"J Immunol Methods"},{"key":"10.1136\/annrheumdis-2012-202220_bib11","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1093\/rheumatology\/kem261","article-title":"Monitoring patients treated with anti-TNF-alpha biopharmaceuticals: assessing serum infliximab and anti-infliximab antibodies","volume":"46","author":"Svenson","year":"2007","journal-title":"Rheumatology (Oxford)."},{"key":"10.1136\/annrheumdis-2012-202220_bib12","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1002\/art.21671","article-title":"Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis","volume":"54","author":"Wolbink","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1136\/annrheumdis-2012-202220_bib13","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.jim.2010.09.005","article-title":"A novel method for the detection of antibodies to adalimumab in the presence of drug reveals \u201chidden\u201d immunogenicity in rheumatoid arthritis patients","volume":"362","author":"van Schouwenburg","year":"2010","journal-title":"J Immunol Methods"},{"key":"10.1136\/annrheumdis-2012-202220_bib14","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1093\/rheumatology\/ker124","article-title":"Influence of immunogenicity on the efficacy of long-term treatment with infliximab in rheumatoid arthritis","volume":"50","author":"Pascual-Salcedo","year":"2011","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/annrheumdis-2012-202220_bib15","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.jim.2011.09.011","article-title":"Antibodies to constant domains of therapeutic monoclonal antibodies: anti-hinge antibodies in immunogenicity testing","volume":"375","author":"Rispens","year":"2012","journal-title":"J Immunol Methods"},{"key":"10.1136\/annrheumdis-2012-202220_bib16","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1001\/jama.283.15.2008","article-title":"Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group","volume":"283","author":"Stroup","year":"2000","journal-title":"JAMA"},{"key":"10.1136\/annrheumdis-2012-202220_bib17","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jclinepi.2009.06.006","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration","volume":"62","author":"Liberati","year":"2009","journal-title":"J Clin Epidemiol"},{"key":"10.1136\/annrheumdis-2012-202220_bib18","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Stat Med"},{"key":"10.1136\/annrheumdis-2012-202220_bib19","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1136\/ard.2008.092833","article-title":"Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis","volume":"68","author":"Radstake","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2012-202220_bib20","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1136\/ard.2006.065615","article-title":"Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis","volume":"66","author":"Bartelds","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2012-202220_bib21","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s00296-006-0183-7","article-title":"Immunogenicity, efficacy and adverse events of adalimumab in RA patients","volume":"27","author":"Bender","year":"2007","journal-title":"Rheumatol Int"},{"key":"10.1136\/annrheumdis-2012-202220_bib22","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1111\/j.1365-2036.2008.03828.x","article-title":"Immunogenicity negatively influences the outcome of adalimumab treatment in Crohn's disease","volume":"28","author":"West","year":"2008","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1136\/annrheumdis-2012-202220_bib23","doi-asserted-by":"crossref","first-page":"310","DOI":"10.3109\/00365521.2010.536254","article-title":"Cut-off levels and diagnostic accuracy of infliximab trough levels and anti-infliximab antibodies in Crohn's disease","volume":"46","author":"Steenholdt","year":"2011","journal-title":"Scand J Gastroenterol"},{"key":"10.1136\/annrheumdis-2012-202220_bib24","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1136\/annrheumdis-2011-200828","article-title":"Influence of immunogenicity on the efficacy of long-term treatment of spondyloarthritis with infliximab","volume":"71","author":"Plasencia","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2012-202220_bib25","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1001\/archdermatol.2009.347","article-title":"Extent and clinical consequences of antibody formation against adalimumab in patients with plaque psoriasis","volume":"146","author":"Lecluse","year":"2010","journal-title":"Arch Dermatol"},{"key":"10.1136\/annrheumdis-2012-202220_bib26","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1111\/j.1365-2133.2011.10555.x","article-title":"Autoantibodies in psoriasis as predictors for loss of response and anti-infliximab antibody induction","volume":"165","author":"Hoffmann","year":"2011","journal-title":"Br J Dermatol"},{"key":"10.1136\/annrheumdis-2012-202220_bib27","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1136\/ard.2008.089979","article-title":"Immunogenicity does not influence treatment with etanercept in patients with ankylosing spondylitis","volume":"68","author":"de Vries","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2012-202220_bib28","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1136\/ard.2009.108787","article-title":"Relationship between the clinical response to adalimumab treatment and serum levels of adalimumab and anti-adalimumab antibodies in patients with psoriatic arthritis","volume":"69","author":"van Kuijk","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2012-202220_bib29","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1136\/annrheumdis-2011-200184","article-title":"Patients non-responding to etanercept obtain lower etanercept concentrations compared with responding patients","volume":"71","author":"Jamnitski","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2012-202220_bib30","doi-asserted-by":"crossref","first-page":"532","DOI":"10.3109\/s10165-011-0567-8","article-title":"Influence of antibodies against infliximab and etanercept on the treatment effectiveness of these agents in Japanese patients with rheumatoid arthritis","volume":"22","author":"Hoshino","year":"2012","journal-title":"Mod Rheumatol"},{"key":"10.1136\/annrheumdis-2012-202220_bib31","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1111\/j.1346-8138.2010.00882.x","article-title":"Anti-infliximab antibody status and its relation to clinical response in psoriatic patients: a pilot study","volume":"37","author":"Adisen","year":"2010","journal-title":"J Dermatol"},{"key":"10.1136\/annrheumdis-2012-202220_bib32","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1136\/gut.2006.099978","article-title":"Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease","volume":"56","author":"Vermeire","year":"2007","journal-title":"Gut"},{"key":"10.1136\/annrheumdis-2012-202220_bib33","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1038\/ajg.2010.9","article-title":"Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease","volume":"105","author":"Afif","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"10.1136\/annrheumdis-2012-202220_bib34","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1136\/ard.2009.112847","article-title":"Anti-infliximab and anti-adalimumab antibodies in relation to response to adalimumab in infliximab switchers and anti-tumour necrosis factor naive patients: a cohort study","volume":"69","author":"Bartelds","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2012-202220_bib35","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1002\/1529-0131(199809)41:9<1552::AID-ART5>3.0.CO;2-W","article-title":"Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis","volume":"41","author":"Maini","year":"1998","journal-title":"Arthritis Rheum"},{"key":"10.1136\/annrheumdis-2012-202220_bib36","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1016\/S0140-6736(99)05246-0","article-title":"Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group","volume":"354","author":"Maini","year":"1999","journal-title":"Lancet"},{"key":"10.1136\/annrheumdis-2012-202220_bib37","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1136\/gut.2006.106781","article-title":"Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial","volume":"56","author":"Sandborn","year":"2007","journal-title":"Gut"},{"key":"10.1136\/annrheumdis-2012-202220_bib38","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S0140-6736(02)08512-4","article-title":"Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial","volume":"359","author":"Hanauer","year":"2002","journal-title":"Lancet"},{"key":"10.1136\/annrheumdis-2012-202220_bib39","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/art.10697","article-title":"Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial","volume":"48","author":"Weinblatt","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1136\/annrheumdis-2012-202220_bib40","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1097\/FPC.0b013e32832a06bf","article-title":"IgG1 heavy chain-coding gene polymorphism (G1m allotypes) and development of antibodies-to-infliximab","volume":"19","author":"Magdelaine-Beuzelin","year":"2009","journal-title":"Pharmacogenet Genomics"},{"key":"10.1136\/annrheumdis-2012-202220_bib41","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1136\/gut.2009.201533","article-title":"The immunogenic part of infliximab is the F(ab\u2032)2, but measuring antibodies to the intact infliximab molecule is more clinically useful","volume":"60","author":"Ben-Horin","year":"2011","journal-title":"Gut"},{"key":"10.1136\/annrheumdis-2012-202220_bib42","doi-asserted-by":"crossref","first-page":"R221","DOI":"10.1186\/ar3208","article-title":"Surprising negative association between IgG1 allotype disparity and anti-adalimumab formation: a cohort study","volume":"12","author":"Bartelds","year":"2010","journal-title":"Arthritis Res Ther"},{"key":"10.1136\/annrheumdis-2012-202220_bib43","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1126\/science.1144603","article-title":"Anti-inflammatory activity of human IgG4 antibodies by dynamic Fab arm exchange","volume":"317","author":"van der Neut Kolfschoten","year":"2007","journal-title":"Science"},{"key":"10.1136\/annrheumdis-2012-202220_bib44","first-page":"40","article-title":"The immunogenicity, safety, and efficacy of etanercept liquid administered once weekly in patients with rheumatoid arthritis","volume":"25","author":"Dore","year":"2007","journal-title":"Clin Exp Rheumatol"},{"key":"10.1136\/annrheumdis-2012-202220_bib45","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1056\/NEJM199901283400401","article-title":"A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate","volume":"340","author":"Weinblatt","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1136\/annrheumdis-2012-202220_bib46","doi-asserted-by":"crossref","first-page":"478","DOI":"10.7326\/0003-4819-130-6-199903160-00004","article-title":"Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial","volume":"130","author":"Moreland","year":"1999","journal-title":"Ann Intern Med"},{"key":"10.1136\/annrheumdis-2012-202220_bib47","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1056\/NEJM200011303432201","article-title":"A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis","volume":"343","author":"Bathon","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1136\/annrheumdis-2012-202220_bib48","doi-asserted-by":"crossref","first-page":"4037","DOI":"10.4049\/jimmunol.172.7.4037","article-title":"Establishment of early lymphoid organ infrastructure in transplanted tumors mediated by local production of lymphotoxin alpha and in the combined absence of functional B and T cells","volume":"172","author":"Kim","year":"2004","journal-title":"J Immunol"},{"key":"10.1136\/annrheumdis-2012-202220_bib49","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1002\/art.27227","volume":"62","author":"Hetland","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1136\/annrheumdis-2012-202220_bib50","first-page":"329","article-title":"Biologic survival","volume":"8","author":"Noiles","year":"2009","journal-title":"J Drugs Dermatol"},{"key":"10.1136\/annrheumdis-2012-202220_bib51","doi-asserted-by":"crossref","first-page":"18","DOI":"10.4081\/reumatismo.2011.18","article-title":"Treatment patterns of anti-TNF agents in Italy: an observational study","volume":"63","author":"Punzi","year":"2011","journal-title":"Reumatismo"},{"key":"10.1136\/annrheumdis-2012-202220_bib52","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1136\/annrheumdis-2012-201544","article-title":"Methotrexate reduces immunogenicity in adalimumab treated rheumatoid arthritis patients in a dose dependent manner","volume":"71","author":"Krieckaert","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2012-202220_bib53","doi-asserted-by":"crossref","first-page":"3782","DOI":"10.1002\/art.22214","article-title":"Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab","volume":"54","author":"Bendtzen","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1136\/annrheumdis-2012-202220_bib54","doi-asserted-by":"crossref","first-page":"R82","DOI":"10.1186\/ar3350","article-title":"Infliximab in ankylosing spondylitis: alone or in combination with methotrexate? A pharmacokinetic comparative study","volume":"13","author":"Mulleman","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"10.1136\/annrheumdis-2012-202220_bib55","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1053\/j.gastro.2009.07.062","article-title":"Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn's disease","volume":"137","author":"Karmiris","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1136\/annrheumdis-2012-202220_bib56","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1002\/art.30209","article-title":"Venous and arterial thromboembolic events in adalimumab-treated patients with antiadalimumab antibodies: a case series and cohort study","volume":"63","author":"Korswagen","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1136\/annrheumdis-2012-202220_bib57","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1053\/j.gastro.2003.11.014","article-title":"Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease","volume":"126","author":"Rutgeerts","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1136\/annrheumdis-2012-202220_bib58","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/S1542-3565(04)00238-1","article-title":"Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease","volume":"2","author":"Hanauer","year":"2004","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1136\/annrheumdis-2012-202220_bib59","first-page":"705","article-title":"ACR and EULAR improvement criteria have comparable validity in rheumatoid arthritis trials. American College of Rheumatology European League of Associations for Rheumatology","volume":"26","author":"van Gestel","year":"1999","journal-title":"J Rheumatol"},{"key":"10.1136\/annrheumdis-2012-202220_bib60","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1136\/ard.62.9.817","article-title":"International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis","volume":"62","author":"Braun","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2012-202220_bib61","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1136\/ard.2008.100826","article-title":"ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis","volume":"68","author":"van der Heijde","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2012-202220_bib62","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1046\/j.1365-2133.1999.02963.x","article-title":"Clinical measures of disease severity and outcome in psoriasis: a critical appraisal of their quality","volume":"141","author":"Ashcroft","year":"1999","journal-title":"Br J Dermatol"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724212796?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724212796?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/annrheumdis-2012-202220","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,5]],"date-time":"2025-01-05T10:21:02Z","timestamp":1736072462000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496724212796"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12]]},"references-count":62,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["S0003496724212796"],"URL":"https:\/\/doi.org\/10.1136\/annrheumdis-2012-202220","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.717969501.793470033","asserted-by":"object"}]},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2013,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: a systematic review of the literature with a meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/annrheumdis-2012-202220","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2022 \u00a9 Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by Elsevier Inc. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}